Cartesian Therapeutics, Inc. (RNAC)
10.17
+0.13
(+1.29%)
USD |
NASDAQ |
Aug 24, 16:00
10.17
0.00 (0.00%)
After-Hours: 20:00
Cartesian Therapeutics Profit Margin (Quarterly)
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -50.23K% |
| December 31, 2025 | -9.78K% |
| September 30, 2025 | -7.94K% |
| June 30, 2025 | |
| March 31, 2025 | -1.61K% |
| September 30, 2024 | -6.25K% |
| June 30, 2024 | 28.79% |
| March 31, 2024 | -973.0% |
| December 31, 2023 | -2.60K% |
| September 30, 2023 | -137.4% |
| June 30, 2023 | -216.9% |
| March 31, 2023 | -364.8% |
| December 31, 2022 | 35.09% |
| September 30, 2022 | -38.11% |
| June 30, 2022 | 21.90% |
| March 31, 2022 | 84.64% |
| December 31, 2021 | 40.88% |
| September 30, 2021 | -73.26% |
| June 30, 2021 | 23.22% |
| March 31, 2021 | -222.6% |
| December 31, 2020 | -129.2% |
| Date | Value |
|---|---|
| September 30, 2020 | -209.4% |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | -223.7% |
| September 30, 2019 | |
| June 30, 2019 | -126.1K% |
| March 31, 2019 | -120.7K% |
| December 31, 2018 | -1.62K% |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | -115.0K% |
| September 30, 2017 | -54.36K% |
| June 30, 2017 | -61.41K% |
| March 31, 2017 | -11.05K% |
| December 31, 2016 | -480.6% |
| September 30, 2016 | -737.4% |
| June 30, 2016 | -343.2% |
| March 31, 2016 | -358.0% |
| March 31, 2015 | -554.4% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Allogene Therapeutics, Inc. | -919.8% |
| Beam Therapeutics, Inc. | -25.04K% |
| C4 Therapeutics, Inc. | -355.9% |
| Kyverna Therapeutics, Inc. | -- |
| Arrowhead Pharmaceuticals, Inc. | -237.8% |
Profit Margin (Quarterly) Related Metrics
| Return on Assets | -46.23% |
| Return on Net Operating Assets | -84.36% |